Caris Life Sciences (CAI) Earnings Analysis
Caris Life Sciences (CAI) has no confirmed upcoming earnings date. Last quarter (2026-02-26) it beat with EPS 0.28 USD vs -0.02 USD est (+1500%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E -9.89.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CAI next report earnings?
No confirmed upcoming earnings date is currently scheduled for CAI. This page updates as the calendar is published.
CAI earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-26 | 0.28 USD | -0.02 USD | +1500% | Beat |
| 2025-08-12 | -0.54 USD | -0.21 USD | -157.1% | Miss |
Beat rate: 1/2 (50%) over reported quarters with consensus data.
CAI valuation and analyst view
| Trailing P/E | -9.89 |
|---|---|
| Trailing EPS | 0.12026 USD |
| Price / book | 7.32 |
| Dividend yield | 0.00% |
| Market cap | 4.38B |
| Analyst consensus | Buy (6 buy / 1 hold / 0 sell) |
| Avg price target | 26.33 USD |
Related research pages
Frequently asked questions
When is Caris Life Sciences (CAI)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for CAI. This page updates as the calendar is published.
Did CAI beat earnings last quarter?
In its 2026-02-26 report, CAI posted EPS of 0.28 USD versus a -0.02 USD estimate — a beat of 1500%.
What is CAI's earnings track record?
Over the last 2 reported quarters with consensus data, CAI beat estimates 1 times (50%).
What is CAI's current P/E ratio and EPS?
CAI trades at a trailing P/E of -9.89 on trailing EPS of 0.12026386575891218 USD.
What do analysts rate CAI?
Analyst consensus is "Buy" across 7 ratings (0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 26.33 USD.